Theorem Clinical Research Expands Partnership with Medidata Solutions

Theorem Clinical Research Expands Partnership with Medidata Solutions
March 13, 2013

KING OF PRUSSIA, Pa.--Theorem Clinical Research, which continues to enhance its ability to help research sponsors optimize trial conduct, recently expanded its Medidata services partnership by obtaining accreditation for Medidata Balance and Medidata Rave Targeted Source Document Verification (TSDV) services.

Medidata Balance accreditation enables Theorem to provide a unified approach to patient data capture and randomization. Clinical investigators and sponsors will gain immediate operational efficiencies while leveraging Theorem's clinical expertise.

"We will be able to transform what can be a lengthy and expensive process into a fast implementation on one platform for subject randomization, supply dispensation and clinical data entry and reporting," said Mark Penniston, senior vice president for clinical analytics.

Theorem also will provide more efficient monitoring services by executing targeted, risk-based source document verification by implementing Medidata Rave TSDV.

"This will help us reduce monitoring costs while improving data quality for our sponsors," Penniston added.

Theorem clinical analytics experts will also be delivering three presentations during the Americas Medidata User Group (A-MUG) meeting in Brooklyn, N.Y., March 18-20:

    - Considerations, Value and Efficiency Gained in Creation of Rave Standards within a CRO Environment, presented by Tami Yudt, senior manager of clinical programming, and Jamie Wildermuth, manager of clinical programming
    - Standardizing for Custom Functions, Edit Checks and Derivations Across Multiple URLs, presented by clinical programmer Rajesh Deshpande
    - How to Reduce the Complex DB Setup Requirements, presented by Mohammed Farooq, associate director of clinical programming

Additionally, CDISC will be the topic of a poster presentation at the FDA/PhUSE Computational Science Symposium March 18-19 in Silver Spring, Md. Nate Freimark, senior director of the Biometrics Operations Standards Group, will be presenting: Bringing Non-CDISC Datasets into a CDISC World with Reproducible Output.

Theorem is one of the industry's leading full-service, global contract research organizations providing core clinical research and development services. Contact Theorem Clinical Research for more information about how to execute successful trials.

About Theorem Clinical Research
Theorem Clinical Research Inc. is a leading midsized provider of comprehensive clinical research and development services with offices in more than 30 countries and a customer base comprised of some of the world's leading pharmaceutical, biotech and medical device companies. A leader in medical device and drug-device combination trials in addition to a notable capability in pharmaceuticals and biologics, Theorem has deep expertise in a broad range of therapeutic areas and in all phases of development. Some of the industry's top scientists and most advanced clinical analytics capabilities help ensure smooth-running, successful trials. For a full-service, right-size global research partner, don't think twice. THINK THEOREM.

Contacts

Theorem Clinical Research
Shawn Clary, 484-679-2400
sha[email protected]

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.